Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men.
A defective, mutated androgen receptor may lead to variable phenotypes of androgen insensitivity in humans. Also, the CAG repeat polymorphism in exon 1 of the androgen receptor gene modulates androgen effects; in vitro, transcription of androgen-dependent target genes is attenuated with increasing length of triplet residues. Clinically, the CAG repeat polymorphism causes significant modulations of androgenicity in various tissues and psychological traits in healthy eugonadal men: the longer the repeat tracts, the less pronounced is the androgen effect when individuals with similar testosterone concentrations are compared. Furthermore, as effects of testosterone substitution are markedly influenced by the number of CAG repeats, the pharmacogenetic implications of this polymorphism are likely to have a significant role in future testosterone treatment of hypogonadal men. Thresholds at which testosterone treatment should be initiated, as well as androgen dosage, might be tailored according to the receptor polymorphism.
Zitzmann
Michael
M
Institute of Reproductive Medicine, Domagkstr. 11, D-48149 Münster, Germany. michael.zitzmann@ukmuenster.de
D000728:Androgens / Q000627:therapeutic use*; D004247:DNA / Q000235:genetics*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D009154:Mutation; D011110:Polymorphism, Genetic; D011944:Receptors, Androgen / Q000187:drug effects / Q000235:genetics*; D013739:Testosterone / Q000627:therapeutic use*; D016896:Treatment Outcome
D000728:Androgens; D011944:Receptors, Androgen; D013739:Testosterone; D004247:DNA